QUERCETA® for Chronic Pelvic Pain. Nonbacterial chronic prostatitis (also known as chronic pelvic pain syndrome or CPPS) affects men of all ages, but is more difficult to diagnose and treat than an infectious prostatitis. Men with CPPS generally suffer from a number of symptoms, including chronic pelvic pain, pain in the penis, testicles, pain after ejaculation, burning with urination, and sensations of pressing and urgent urination. Standard treatments are based on the combination of antibiotics and muscle relaxants. However, clinical studies suggest that natural supplements are more effective.
Clinical studies report that 500 mg of Quercetin, administered twice daily contribute to a significant reduction in pain in patients with CPPS. Moreover, it has been shown that Zinc and Lycopene could help maintain prostate health, reduce the symptoms of CPPS and prevent the onset of cancer. Finally, there is evidence that vitamin D, a natural anti -inflammatory can reduce the risk of cancer, including prostate cancer.
Quercetin has strong antioxidant, anti-inflammatory and antineoplastic properties.
The prevalence of cancer and prostate inflammation is reaching epidemic levels, suggesting a link between those two pathologies. Chronic inflammation is known to present neoplastic risks and may promote the creation of a niche favorable to the emergence of cancer.
Therefore, the use of Querceta is indicated to relieve pain and symptoms in men with CPPS, and its use may also reduce the incidence of prostate cancer.
Approved by Health Canada. NPN: 80042459
Recommended Dose: 2 capsules per day
- Quercetin: 500mg
- Zinc: 10 mg
- Lycopene: 3.5 mg
- Vitamin D: 12.5 mcg (500 IU)
- Shoskes, D. A. & Manickam, K. Herbal and complementary medicine in chronic prostatitis. World J Urol 21, 109-113, doi:10.1007/s00345-003-0332-5 (2003)./li>
- Shoskes, D. A., Zeitlin, S. I., Shahed, A. & Rajfer, J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 54, 960-963 (1999).
- Duclos, A. J., Lee, C. T. & Shoskes, D. A. Current treatment options in the management of chronic prostatitis. Ther Clin Risk Manag 3, 507-512 (2007).
- Shoskes, D. A. Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceutic Assoc, 18–21. (1999).
- Shoskes, D. A. & Nickel, J. C. Quercetin for chronic prostatitis/chronic pelvic pain syndrome. Urol Clin North Am 38, 279-284, doi:10.1016/j.ucl.2011.05.003 (2011).
- Goodarzi, D., Cyrus, A., Baghinia, M. R., Kazemifar, A. M. & Shirincar, M. The efficacy of zinc for treatment of chronic prostatitis. Acta Med Indones 45, 259-264 (2013).
- Costello, L. C., Franklin, R. B., Zou, J. & Naslund, M. J. Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach. Chemotherapy (Los Angel) 4, doi:10.4172/2167-7700.1000152 (2015).
- Wertz, K. Lycopene effects contributing to prostate health. Nutr Cancer 61, 775-783, doi:10.1080/01635580903285023 (2009).
- Magri, V., Marras, E., Restelli, A., Wagenlehner, F. M. & Perletti, G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. g.
- Lombardo, F. et al. Effects of a dietary supplement on chronic pelvic pain syndrome (Category IIIA), leucocytospermia and semen parameters. Andrologia 44 Suppl 1, 672-678, doi:10.1111/j.1439-0272.2011.01248.x (2012).
- Li, Y., Ahmad, A., Kong, D., Bao, B. & Sarkar, F. H. Recent progress on nutraceutical research in prostate cancer. Cancer Metastasis Rev 33, 629-640, doi:10.1007/s10555-013-9478-9 (2014).
- Hoang, B. X., Han, B., Shaw, D. G. & Nimni, M. Zinc as a possible preventive and therapeutic agent in pancreatic, prostate, and breast cancer. Eur J Cancer Prev, doi:10.1097/CEJ.0000000000000194 (2015).
- Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. & Feldman, B. J. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14, 342-357, doi:10.1038/nrc3691 (2014).
- Foresta, C. et al. Bone mineral density and testicular failure: evidence for a role of vitamin D 25-hydroxylase in human testis. J Clin Endocrinol Metab 96, E646-652, doi:10.1210/jc.2010-1628 (2011).
- Taverna, G. et al. Inflammation and prostate cancer: friends or foe? Inflamm Res 64, 275-286, doi:10.1007/s00011-015-0812-2 (2015).
- Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545, doi:10.1016/S0140-6736(00)04046-0 (2001).
- Curtis Nickel, J., Shoskes, D., Roehrborn, C. G. & Moyad, M. Nutraceuticals in Prostate Disease: The Urologist’s Role. Rev Urol 10, 192-206 (2008).
- Platz, E. A. & De Marzo, A. M. Epidemiology of inflammation and prostate cancer. J Urol 171, S36-40, doi:10.1097/01.ju.0000108131.43160.77 (2004).
- Palapattu, G. S. et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26, 1170-1181, doi:10.1093/carcin/bgh317 (2005).
- Clevers, H. At the crossroads of inflammation and cancer. Cell 118, 671-674, doi:10.1016/j.cell.2004.09.005 (2004).